Serplulimab

CAS No. 2231029-82-4

Serplulimab( —— )

Catalog No. M36682 CAS No. 2231029-82-4

Serplulimab (HLX 10) is a humanized monoclonal anti-antibody to PD-1. Serplulimab has antitumor activity and can be used in small cell lung cancer and esophageal squamous cell carcinoma.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 353 In Stock
10MG 567 In Stock
25MG 888 In Stock
50MG 1172 In Stock
100MG 1572 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Serplulimab
  • Note
    Research use only, not for human use.
  • Brief Description
    Serplulimab (HLX 10) is a humanized monoclonal anti-antibody to PD-1. Serplulimab has antitumor activity and can be used in small cell lung cancer and esophageal squamous cell carcinoma.
  • Description
    Serplulimab (HLX 10) is humanized monoclonal anti-PD-1 antibody. Serplulimab can be used in research of small cell lung cancer.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Chromatin/Epigenetic
  • Target
    COX
  • Recptor
    COX
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2231029-82-4
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Lee A. Serplulimab: First Approval. Drugs. 2022 Jul;82(10):1137-1141.?
molnova catalog
related products
  • Amentoflavone

    Amentoflavone can interact with many other medications by being a potent inhibitor of CYP3A4 and CYP2C9.

  • Orientin

    Orientin may be regarded as a candidate therapeutic agent for treatment of vascular inflammatory diseases via inhibition of the HMGB1 signaling pathway.

  • Inulicin

    Inulicin, an active compound isolated from Inula Britannica L, inhibits VEGF-mediated activation of Src and FAK.